cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.48577/jpl.llnima
title: Thermal Phase Curves in Hot Gas Giant Exoplanets Exhibit a Complex Dependence on Planetary Properties

description: We present a catalog of uniformly processed 3.6-μm and 4.5-μm band exoplanet thermal phase curves based on Infrared Array Camera observations obtained from the Spitzer Heritage Archive. The catalog includes phase curve measurements for 34 planets, 16 of which contain full orbit coverage and have detectable secondary eclipses in both channels. The data are processed in the EXCALIBUR pipeline using a uniform analysis consisting of aperture photometry and modeling of instrument effects along with the exoplanet signal. Nearest-neighbors regression with a Gaussian kernel is used to correct for instrumental systematics correlated to the star’s centroid position and shape in conjunction with a novel test to avoid overfitting. These methods may have utility in addressing sub-pixel gain variations presentin modern infrared detectors. We analyze the 3.6-μm and 4.5-μm phase curve properties and find a strong wavelength-dependent difference in how the properties correlate with physical parameters as well as evidence that the phase curve properties are determined by multiple physical parameters. We suggest that differences between the 3.6-μm and 4.5-μm phase curve properties are due to 3.6 μm observations probing regions of the atmosphere which could include a cloud layer. Taken together, the observed phase curve behavior suggests that different physical processes are responsible for establishing the thermal phase curve at different pressures, which are probed by different wavelengths, and that further 3D GCM modeling is required to investigate the reason for this complex dependence on planetary properties.
DOI: 10.48577/jpl.msgfay
title: Gauss-Radau Small-body Simulator (GRSS): An Open-Source Library for Planetary Defense

description: We present GRSS, a small-body propagation and orbit determination library specifically designed for planetary defense applications. GRSS is an end-to-end, open-source software tool that begins with optical observations obtained from the Minor Planet Center and Gaia spacecraft, as well as radar observations from the Jet Propulsion Laboratory, and ends with reliable predictions about the trajectory of a small body in the solar system. The library is built on a C++11 orbit propagation core and provides additional orbit determination capability through a Python interface for ease of use. We conducted extensive validation for both of these components of the library by comparing them with the state-of-the-art operational software tools. We demonstrate the capabilities of GRSS by applying it to orbit propagation for (65803) Didymos and orbit determination for (29075) 1950 DA. We also used GRSS to calculate the keyholes for the 2135 close encounter of (101955) Bennu and determine the impact location for 2024 BX1 and 2024 RW1. The library is designed to be modular and extensible, allowing for future addition of additional orbit filters as well as dynamical models. GRSS is publicly available on GitHub under a GPLv3 license and is intended to be a community resource for planetary science and planetary defense.
DOI: 10.48577/jpl.uprlzj
title: Testing for Intrinsic SN Ia Luminosity Evolution at z &gt; 2 with JWST

description: The James Webb Space Telescope (JWST) is opening new frontiers of transient discovery and follow-up at high-redshift. Here we present the discovery of a spectroscopically confirmed SN Ia (SN 2023aeax) at z = 2.15 with JWST, with cadenced NIRCam observations that enable multi-band light curve fitting. SN 2023aeax lands at the edge of traditional low-z cosmology color cuts because of its blue color (peak rest-frame B−V ∼ −0.3), but we still apply a fiducial standardization approach with the BayeSN model and find that the SN2023aeax luminosity distance measurement is in agreement (∼ 0.1σ) with ΛCDM. SN 2023aeax is only the second spectroscopically confirmed SN Ia in the dark matter-dominated Universe at z &gt; 2 (the other is SN 2023adsy), giving it rare leverage to constrain any potential evolution in SN Ia standardized luminosities. Similar to SN2023adsy (B − V ∼ 0.8), SN 2023aeax has a fairly extreme (but opposite) color, which may be due to the small sample size or a secondary factor, such as host galaxy properties. Nevertheless, the SN 2023aeax spectrum is wellrepresented by normal low-z SN Ia spectra and we find no definitive evolution in SN Ia standardization with redshift. Still, the first two spectroscopically confirmed z &gt; 2 SNe Ia have peculiar colors and combine for a ∼ 1σ distance slope relative to ΛCDM, the implications of which require a larger sample and dedicated host galaxy observations to investigate.
DOI: 10.25934/pr00005748.5
title: Available IPD datapackage for study 'A Randomized, Multicenter, Phase III Open-label Study of the Efficacy and Safety of Trastuzumab MCC-DM1 vs. Capecitabine + Lapatinib in Patients With HER2-Positive Locally Advanced or Metastatic Breast Cancer Who Have Received Prior Trastuzumab-Based Therapy'

description: This is a Phase III, randomized, multicenter, international, 2-arm, open-label clinical trial designed to compare the safety and efficacy of trastuzumab emtansine (T-DM1) with that of capecitabine + lapatinib in participants with human epidermal growth factor receptor 2 (HER2)-positive locally advanced or metastatic breast cancer. Participants will be treated until disease progression (PD), unmanageable toxicity, or study termination. Once disease progression is reported, all participants will be followed for survival every 3 months until death, loss to follow-up, withdrawal of consent, or study termination.
DOI: 10.25934/pr00008303.0
title: Available datapackage for study 'A Multicenter Phase III Randomized Trial of Adjuvant Therapy for Patients With HER2-Positive Node-Positive or High Risk Node-Negative Breast Cancer Comparing Chemotherapy Plus Trastuzumab With Chemotherapy Plus Trastuzumab Plus Bevacizumab'

description: The trial will determine the value of adding bevacizumab to chemotherapy plus trastuzumab in patients with resected node-positive or high risk node-negative, HER2-positive breast cancer.
DOI: 10.25934/pr00005703.2
title: Available IPD datapackage for study 'A Randomized, Open-label Study to Compare the Effect of First-line Treatment With Avastin in Combination With Herceptin/Docetaxel and Herceptin/Docetaxel Alone on Progression-free Survival in Patients With HER2 Positive Locally Recurrent or Metastatic Breast Cancer.'

description: This 2 arm study will compare the efficacy and safety of Avastin plus Herceptin/docetaxel, versus Herceptin/docetaxel alone, in patients with HER2 positive locally recurrent or metastatic breast cancer who have not received prior chemotherapy for their metastatic disease. Patients will be randomized 1:1 to receive either Avastin (15mg/kg iv q3weeks) + Herceptin (8mg/kg iv loading dose and 6mg/kg iv q3weeks maintenance) + docetaxel (100mg/m2 iv q3weeks) or Herceptin + docetaxel alone. The anticipated time on study treatment is until disease progression, and the target sample size is 100-500 individuals.
DOI: 10.25934/pr00008284.0
title: Available datapackage for study 'A Randomized, Open-label Study of the Effect of Paclitaxel, Doxorubicin, and CMF Neoadjuvant Chemotherapy, With and Without Herceptin, on Tumor Response in Women With HER2-positive Breast Cancer'

description: This study will assess the efficacy and safety of adding Herceptin to a paclitaxel-containing regimen followed by cyclophosphamide/methotrexate/fluorouracil (CMF) chemotherapy in women with locally advanced breast cancer and HER2/c-erbB-2 gene amplification. In a parallel observational study patients with HER2-negative disease will receive the same chemotherapy without Herceptin.
DOI: 10.25934/pr00006059.2
title: Available IPD datapackage for study 'A Two-Cohort, Open-Label, Multicenter Study of Trastuzumab Emtansine (T-DM1) in HER2-Positive Locally Advanced or Metastatic Breast Cancer Patients Who Have Received Prior Anti-HER2 and Chemotherapy-Based Treatment'

description: This two-cohort, open-label, multicenter study will assess the safety, efficacy and tolerability of trastuzumab emtansine in participants with HER2-positive locally advanced breast cancer (LABC) or metastatic breast cancer (mBC) who have received prior anti-HER2 and chemotherapy-based treatment. Participants in Cohort 1 will be drawn from the general participant population; Cohort 2 will include only Asian participants.
DOI: 10.25934/pr00011028.0
title: Available datapackage for study 'A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial To Evaluate the Efficacy and Safety Of Atezolizumab or Placebo in Combination With Neoadjuvant Doxorubicin + Cyclophosphamide Followed By Paclitaxel + Trastuzumab + Pertuzumab In Early Her2-Positive Breast Cancer'

description: This study (also known as IMpassion050) will evaluate the efficacy and safety of atezolizumab compared with placebo when given in combination with neoadjuvant dose-dense anthracycline (doxorubicin) + cyclophosphamide followed by paclitaxel + trastuzumab + pertuzumab (ddAC-PacHP) in patients with early HER2-positive breast cancer (T2-4, N1-3, M0).
DOI: 10.5281/zenodo.14919176
title: Data for Globalisation & Patents Paper
DOI: 10.5281/zenodo.14919177
title: Data for Globalisation & Patents Paper
DOI: 10.25934/pr00006469.5
title: Available IPD datapackage for study 'A Randomized Multicenter, Double-Blind, Placebo-Controlled Comparison of Chemotherapy Plus Trastuzumab Plus Placebo Versus Chemotherapy Plus Trastuzumab Plus Pertuzumab as Adjuvant Therapy in Patients With Operable HER2-Positive Primary Breast Cancer'

description: This randomized, double-blind, placebo-controlled, two-arm study will assess the safety and efficacy of pertuzumab in addition to chemotherapy plus trastuzumab as adjuvant therapy in participants with operable HER2-positive primary breast cancer. This study will be carried out in collaboration with the Breast International Group (BIG).
DOI: 10.5281/zenodo.14919186
title: TRICKS USED BY BORDER CROSSERS ILLEGALLY CROSSING THE STATE BORDER
DOI: 10.5281/zenodo.14919187
title: TRICKS USED BY BORDER CROSSERS ILLEGALLY CROSSING THE STATE BORDER
DOI: 10.25934/pr00006725.4
title: Available IPD datapackage for study 'A Randomized, Multicenter, Open-Label Phase III Study to Evaluate the Efficacy and Safety of Trastuzumab Emtansine Versus Trastuzumab as Adjuvant Therapy for Patients With HER2-Positive Primary Breast Cancer Who Have Residual Tumor Present Pathologically in the Breast or Axillary Lymph Nodes Following Preoperative Therapy'

description: This 2-arm, randomized, open-label study will evaluate the efficacy and safety of trastuzumab emtansine versus trastuzumab as adjuvant therapy in patients with HER2-positive breast cancer who have residual tumor present in the breast or axillary lymph nodes following preoperative therapy. Eligible patients will be randomized to receive either trastuzumab emtansine 3.6 mg/kg or trastuzumab 6 mg/kg intravenously every 3 weeks for 14 cycles. Radiotherapy and/or hormone therapy will be given in addition if indicated.
DOI: 10.25934/pr00005698.5
title: Available IPD datapackage for study 'A Randomised, Double Blind, Placebo Controlled, Multicentre Study to Evaluate the Efficacy and Safety of Bevacizumab in Combination With Docetaxel in Comparison With Docetaxel Plus Placebo, as First Line Treatment for Patients With HER2 Negative Metastatic and Locally Recurrent Breast Cancer.'

description: This study will evaluate the efficacy and safety of 2 doses of Avastin in combination with docetaxel, versus docetaxel plus placebo, in patients with metastatic HER2 negative breast cancer who are candidates for taxane-based chemotherapy but who have not received prior chemotherapy for metastatic disease. The anticipated time on treatment is 1-2 years and the target sample size is 500+ individuals.
DOI: 10.25934/pr00005651.5
title: Available IPD datapackage for study 'A Randomized Three-Arm, Multicenter Comparison of 1 Year and 2 Years of Herceptin Versus No Herceptin in Women With HER2-Positive Primary Breast Cancer Who Have Completed Adjuvant Chemotherapy'

description: The purpose of this trial is to evaluate Herceptin treatment for 1 year and 2 years (versus observation/no Herceptin) in women with HER2-overexpressing primary breast cancer who have completed (neo-)adjuvant systemic chemotherapy, definitive surgery, and radiotherapy, if applicable. Efficacy and safety will be assessed for 10 years from randomization for each participant. All participants will continue to be followed for survival until 10 years after enrollment of the last participant.
DOI: 10.15468/dl.w5es76
title: Occurrence Download

description: A dataset containing 93 species occurrences available in GBIF matching the query:
{
 "and" : [
 "DatasetKey is Lichen herbarium, UiB",
 "Country is Croatia"
 ]
}

 The dataset includes 93 records from 1 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0003416-250221090833381/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.25934/pr00005688.2
title: Available IPD datapackage for study 'A Phase III, Multicenter, Randomized, Placebo-controlled Trial Evaluating the Efficacy and Safety of Bevacizumab in Combination With Chemotherapy Regimens in Subjects With Previously Treated Metastatic Breast Cancer'

description: This phase III, multicenter, randomized, placebo-controlled, blinded trial is designed to evaluate the efficacy and safety of bevacizumab when combined with standard chemotherapy compared with chemotherapy alone in subjects with previously treated metastatic breast cancer.
DOI: 10.15468/dl.3v47ua
title: Occurrence Download

description: A dataset containing 108 species occurrences available in GBIF matching the query:
{
 "and" : [
 "Continent is Africa",
 "Country is Côte d’Ivoire",
 "TaxonKey is Xylopia villosa Chipp"
 ]
}

 The dataset includes 108 records from 17 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0003415-250221090833381/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.wyx97q
title: Occurrence Download

description: A dataset containing 37 species occurrences available in GBIF matching the query:
{
 "and" : [
 "Continent is Africa",
 "Country is Côte d’Ivoire",
 "TaxonKey is Placodiscus boya Aubrév. & Pellegr."
 ]
}

 The dataset includes 37 records from 9 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0003417-250221090833381/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.4jmhax
title: Occurrence Download

description: A dataset containing 671 species occurrences available in GBIF matching the query:
{
 "and" : [
 "DatasetKey is Vascular Plant Herbarium, Oslo (O) UiO",
 "Country is Croatia"
 ]
}

 The dataset includes 671 records from 1 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0003418-250221090833381/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.gp2fg6
title: Occurrence Download

description: A dataset containing 25 species occurrences available in GBIF matching the query:
{
 "and" : [
 "DatasetKey is Biofokus",
 "Country is Croatia"
 ]
}

 The dataset includes 25 records from 1 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0003419-250221090833381/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.wfu8h5
title: Occurrence Download

description: A dataset containing 1315 species occurrences available in GBIF matching the query:
{
 "TaxonKey" : [
 "is Coffea liberica Bull. ex Hiern"
 ]
}

 The dataset includes 1315 records from 97 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0003420-250221090833381/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.25934/pr00005994.2
title: Available IPD datapackage for study 'A Phase III Prospective, Two-Cohort Non-Randomized, Multi-Centre, Multinational, Open-Label Study to Assess the Safety of Assisted- and Self-Administered Subcutaneous Trastuzumab as Therapy in Patients With Operable HER2-Positive Early Breast Cancer'

description: This multicenter, two-cohort, non-randomized, open-label study will evaluate the safety and tolerability of assisted and self-administered SC Herceptin as adjuvant therapy in participants with early HER2-positive breast cancer following tumor excision. Participants will receive Herceptin 600 milligrams (mg) SC every 3 weeks for 18 cycles, either by an assisted administration using a conventional syringe and needle/vial formulation (Cohort A) or with assisted and self-administration using a single-use injection device (SID) in selected participants (Cohort B).
DOI: 10.25934/pr00006653.2
title: Available IPD datapackage for study 'A Multicenter Randomized Phase III Study to Compare the Combination Trastuzumab and Capecitabine, With or Without Pertuzumab, in Patients With HER2-Positive Metastatic Breast Cancer That Have Progressed After One Line of Trastuzumab-Based Therapy in the Metastatic Setting (PHEREXA)'

description: This randomized, two-arm study evaluated the efficacy and safety of a combination of trastuzumab and capecitabine with or without pertuzumab in patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer. The study population consisted of female patients, whose disease had progressed during or following previous trastuzumab therapy for metastatic disease. All patients in Arm A and Arm B received trastuzumab (8 mg/kg iv as loading dose and then 6 mg/kg iv every 3 weeks thereafter) and capecitabine oral twice daily for 14 days every 3 weeks (1250 mg/m2 twice daily in Arm A and 1000 mg/m2 twice daily in Arm B). In addition, patients in Arm B received pertuzumab (840 mg iv as loading dose and then 420 mg iv thereafter) every 3 weeks. Study treatment continued until disease progression or unacceptable toxicity.
DOI: 10.15468/dl.rk9x9x
title: Occurrence Download

description: A dataset containing 1167363 species occurrences available in GBIF matching the query:
{
 "and" : [
 "Geometry POLYGON((-76.17462 9.1203,-74.46119 9.1203,-74.46119 10.82571,-76.17462 10.82571,-76.17462 9.1203))",
 "HasCoordinate is true",
 "HasGeospatialIssue is false",
 "OccurrenceStatus is Present",
 "Year 1985-2025"
 ]
}

 The dataset includes 1167363 records from 419 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0003397-250221090833381/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.5281/zenodo.14919194
title: UNIQUE LINGUISTIC TOOLS IN THE TEXT OF SOATOY KAMAL KIZI'S POEMS
DOI: 10.5281/zenodo.14919195
title: UNIQUE LINGUISTIC TOOLS IN THE TEXT OF SOATOY KAMAL KIZI'S POEMS
DOI: 10.25934/pr00005649.1
title: Available IPD datapackage for study 'A Randomized, Open-label Study of the Effect of Herceptin Plus Arimidex Compared With Arimidex Alone on Progression-free Survival in Patients With HER2-positive and Hormone-receptor Positive Metastatic Breast Cancer'

description: This 2 arm study assessed the safety and efficacy of adding intravenous trastuzumab (Herceptin®) to daily oral anastrozole (Arimidex®) tablets as first- and second-line treatment in postmenopausal patients with human epidermal growth factor receptor-2 (HER2) overexpressing metastatic breast cancer (ER+ve and/or PR+ve). Patients were randomized to receive either anastrazole 1 mg per os (po) daily, or anastrazole 1 mg po daily + a loading dose of Herceptin® 4 mg/kg intravenous (iv) followed by weekly doses of Herceptin® 2 mg/kg iv. The anticipated time on study treatment was until disease progression, and the target sample size was 100-500 individuals.
DOI: 10.15468/dl.s5a9vq
title: Occurrence Download

description: A dataset containing 216 species occurrences available in GBIF matching the query:
{
 "and" : [
 "DatasetKey is Vascular plant herbarium TRH, NTNU University Museum",
 "Country is Croatia"
 ]
}

 The dataset includes 216 records from 1 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0003423-250221090833381/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.5ssy9a
title: Occurrence Download

description: A dataset containing 326 species occurrences available in GBIF matching the query:
{
 "and" : [
 "DatasetKey is Algae herbarium TRH, NTNU University Museum",
 "Country is Croatia"
 ]
}

 The dataset includes 326 records from 1 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0003422-250221090833381/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.25318/3610023401-fra
title: Produit intérieur brut touristique, prix constants

description: Données trimestrielles réelles.
DOI: 10.25934/pr00006831.3
title: Available IPD datapackage for study 'A RANDOMIZED, MULTICENTER, DOUBLE-BLIND PHASE 3 STUDY OF PD-0332991 (ORAL CDK 4/6 INHIBITOR) PLUS LETROZOLE VERSUS PLACEBO PLUS LETROZOLE FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH ER (+), HER2 (-) BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTI CANCER TREATMENT FOR ADVANCED DISEASE'

description: The study is designed to compare the clinical benefit following treatment with letrozole in combination with PD-0332991 versus letrozole in combination with placebo in postmenopausal women with ER(+)/HER2(-) advanced breast cancer who have not received prior systemic anti cancer therapies for their advanced/metastatic disease.
DOI: 10.25934/pr00011035.0
title: Available datapackage for study 'A Phase III, Double-blind, Placebo-controlled, Randomized Study of Ipatasertib in Combination With Atezolizumab and Paclitaxel as a Treatment for Patients With Locally Advanced Unresectable or Metastatic Triple-Negative Breast Cancer'

description: This study evaluated the efficacy and safety of ipatasertib in combination with atezolizumab and paclitaxel in locally advanced or metastatic Triple-Negative Breast Cancer (TNBC) previously untreated in this setting.
DOI: 10.25934/pr00005579.3
title: Available IPD datapackage for study 'A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study To Evaluate the Efficacy and Safety Of Bevacizumab, and Associated Biomarkers, In Combination With Paclitaxel Compared With Paclitaxel Plus Placebo as First-line Treatment Of Patients With Her2-Negative Metastatic Breast Cancer'

description: This is a Phase III, randomized, double-blind, placebo-controlled multicenter study to evaluate the efficacy and safety of bevacizumab administered in combination with paclitaxel in patients with previously untreated, locally recurrent, or metastatic HER2-negative breast cancer. Patients will be randomized to one of two treatment arms: bevacizumab or placebo. All patients will be given an intravenous (IV) infusion of of paclitaxel (90 mg/m2) for 3 weeks during each 28-day cycle. bevacizumab or placebo (10 mg/kg) will be administered by IV infusion on Days 1 and 15 of each 28-day cycle. Patients will be treated until disease progression, unacceptable toxicity or death from any cause occurs.